Download PDF
Semin Thromb Hemost 2025; 51(01): 018-022
DOI: 10.1055/s-0044-1791778
Review Article

Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

Maria Elisa Mancuso
1   Department of Cardiovascular Diseases, Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
2   Humanitas University, Pieve Emanuele, Milan, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The mainstay of treatment for persons with hemophilia A (PwHA) with severe bleeding phenotype is prophylaxis. The pharmacokinetic (PK) profile of native factor VIII (FVIII) imposes the need for rather frequent intravenous injections to ensure effective prophylaxis, but this represents a relevant treatment burden and is associated with suboptimal adherence to treatment. In this light, the advent of extended half-life (EHL) FVIII molecules has improved prophylaxis feasibility and outcomes by favoring treatment individualization and tailoring protection according to specific clinical and nonclinical needs. Different technologies have been used to enhance FVIII PK properties including Fc-fusion and conjugation with polyethylene glycol. Data from clinical development programs for such molecules, together with growing real-world experience, have shown numerous benefits related to the use of EHL FVIII in PwHA. Recently a new class of ultra-long-acting EHL FVIII has been developed to further improve protection against bleeding episodes and achieve the ambitious goal of providing PwHA with hemostatic protection in the nonhemophilia range over longer time periods, hence ensuring very low bleeding rates and improving joint health and quality of life. In this review, the achievements and perspectives of replacement therapies for PwHA are summarized and discussed.

Keywords

hemophilia A - factor VIII - EHL-FVIII - efanesoctocog alfa - prophylaxis


Publication History

Article published online:
14 October 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Srivastava A, Santagostino E, Dougall A. et al. WFH Guidelines for the Management of Hemophilia. 3rd ed. Haemophilia 2020; 26 (Suppl 6): 1-158
    CrossrefPubMedSearch in Google Scholar
  • 2 Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65 (02) 129-135
    CrossrefPubMedSearch in Google Scholar
  • 3 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (01) 25-32
    CrossrefPubMedSearch in Google Scholar
  • 4 Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021; 397 (10274): 630-640
    CrossrefPubMedSearch in Google Scholar
  • 5 Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13 (Suppl. 02) 16-22
    CrossrefPubMedSearch in Google Scholar
  • 6 Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125 (13) 2038-2044
    CrossrefPubMedSearch in Google Scholar
  • 7 Iorio A, Iserman E, Blanchette V. et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017; 23 (03) e170-e179
    CrossrefPubMedSearch in Google Scholar
  • 8 Megías-Vericat JE, Bonanad Boix S, Berrueco Moreno R. et al. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. Thromb Res 2022; 216: 35-42
    CrossrefPubMedSearch in Google Scholar
  • 9 Matino D, Germini F, Chan AKC. et al. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia 2024; 30 (02) 345-354
    CrossrefPubMedSearch in Google Scholar
  • 10 Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E. Defining extended half-life rFVIII: a critical review of the evidence. Haemophilia 2018; 24 (03) 348-358
    CrossrefPubMedSearch in Google Scholar
  • 11 Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 2015; 169 (06) 768-776
    CrossrefPubMedSearch in Google Scholar
  • 12 Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective. Crit Rev Oncol Hematol 2022; 174: 103678
    CrossrefPubMedSearch in Google Scholar
  • 13 Königs C, Ozelo MC, Dunn A. et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood 2022; 139 (26) 3699-3707
    CrossrefPubMedSearch in Google Scholar
  • 14 Blatný J, Nielsen EM, Reitzel SB. et al. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: a systematic literature review of treatment experience in Europe. Haemophilia 2023; 29 (04) 963-974
    CrossrefPubMedSearch in Google Scholar
  • 15 Sidonio Jr RF, Thompson AA, Peyvandi F. et al. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study. Expert Rev Hematol 2023; 16 (10) 793-801
    CrossrefPubMedSearch in Google Scholar
  • 16 Klamroth R, Windyga J, Radulescu V. et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood 2021; 137 (13) 1818-1827
    CrossrefPubMedSearch in Google Scholar
  • 17 Kenet G, Young G, Chuansumrit A. et al. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results. J Thromb Haemost 2023; 21 (11) 3109-3116
    CrossrefPubMedSearch in Google Scholar
  • 18 Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M. PROTECT VIII Kids: BAY 94-9027 (PEGylated recombinant factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia 2020; 26 (03) e55-e65
    CrossrefPubMedSearch in Google Scholar
  • 19 Santagostino E, Lalezari S, Ducore J. et al. BAY 94–9027 is efficacious in maintaining hemostasis during major surgery in adults and adolescents with severe hemophilia A: PROTECT VIII results. Haemophilia 2018; 24 (Suppl1): 69
    PubMedSearch in Google Scholar
  • 20 Gruppo R, López-Fernández MF, Wynn TT, Engl W, Sharkhawy M, Tangada S. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial. Haemophilia 2019; 25 (05) 773-781
    CrossrefPubMedSearch in Google Scholar
  • 21 Tosetto A, Neff A, Lentz SR. et al. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: full data set from the pathfinder 3 and 5 phase III trials. Haemophilia 2020; 26 (03) 450-458
    CrossrefPubMedSearch in Google Scholar
  • 22 Chowdary P, Holmström M, Mahlangu JN. et al. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: data on safety and effectiveness from phase 3 pivotal studies. Res Pract Thromb Haemost 2022; 6 (05) e12760
    CrossrefPubMedSearch in Google Scholar
  • 23 Skinner MW, Nugent D, Wilton P. et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia 2020; 26 (01) 17-24
    CrossrefPubMedSearch in Google Scholar
  • 24 Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood 2016; 128 (16) 2007-2016
    CrossrefPubMedSearch in Google Scholar
  • 25 Dargaud Y, Leuci A, Ruiz AR, Lacroix-Desmazes S. Efanesoctocog alfa: the renaissance of factor VIII replacement therapy. Haematologica 2024; 109 (08) 2436-2444
    PubMedSearch in Google Scholar
  • 26 Konkle BA, Shapiro AD, Quon DV. et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020; 383 (11) 1018-1027
    CrossrefPubMedSearch in Google Scholar
  • 27 Lissitchkov T, Willemze A, Katragadda S, Rice K, Poloskey S, Benson C. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv 2022; 6 (04) 1089-1094
    CrossrefPubMedSearch in Google Scholar
  • 28 von Drygalski A, Chowdary P, Kulkarni R. et al; XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388 (04) 310-318
    CrossrefPubMedSearch in Google Scholar
  • 29 Malec L, Peyvandi F, Chan AKC. et al; XTEND-Kids Trial Group. Efanesoctocog alfa prophylaxis for children with severe hemophilia A. N Engl J Med 2024; 391 (03) 235-246
    CrossrefPubMedSearch in Google Scholar
  • 30 Chan A, Susen S, Khoo L. et al. Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program. Paper presented at: the 32nd ISTH Congress; June 22–26, 2024 ; Bangkok, Thailand
    PubMedSearch in Google Scholar
  • 31 Malec L, Nolan B, Chan A. et al. Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study. Paper presented at: the 32nd ISTH Congress; June 22–26, 2024 ; Bangkok, Thailand
    PubMedSearch in Google Scholar
  • 32 Susen S, P'ng S, Lissitchkov T. et al. First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study. Paper presented at: the 32nd ISTH Congress; June 22–26, 2024 ; Bangkok, Thailand
    PubMedSearch in Google Scholar
  • 33 Von Drygalski A, Königs C, Konkle B. et al. Interim analysis of joint outcomes in adult and adolescent patients with severe hemophilia A receiving efanesoctocog alfa during the phase 3 XTEND-ed long-term extension study. Paper presented at: the 32nd ISTH Congress; June 22–26, 2024 ; Bangkok, Thailand
    PubMedSearch in Google Scholar
  • 34 Krumb E, Hermans C. Living with a “hemophilia-free mind”: the new ambition of hemophilia care?. Res Pract Thromb Haemost 2021; 5 (05) e12567
    CrossrefPubMedSearch in Google Scholar
  • 35 van Leeuwen FHP, van Bergen EDP, Timmer MA. et al. Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis. J Thromb Haemost 2023; 21 (05) 1156-1163
    CrossrefPubMedSearch in Google Scholar